NMDP Celebrates 10,000th Unrelated Donor Transplant

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

MINNEAPOLIS-The National Marrow Donor Program (NMDP) has reached a new milestone: 10,000 unrelated donor transplants. “At our 10-year anniversary in 1997, we celebrated 6,000 unrelated transplants, but in just 3 years, we have increased that number to 10,000,” Dr. Dennis Confer, chief medical office, said in a news release. The program, which has a volunteer registry of more than 4 million potential donors, facilitates transplants for more than 120 patients each month, he said.

MINNEAPOLIS—The National Marrow Donor Program (NMDP) has reached a new milestone: 10,000 unrelated donor transplants. “At our 10-year anniversary in 1997, we celebrated 6,000 unrelated transplants, but in just 3 years, we have increased that number to 10,000,” Dr. Dennis Confer, chief medical office, said in a news release. The program, which has a volunteer registry of more than 4 million potential donors, facilitates transplants for more than 120 patients each month, he said.

The NMDP has scheduled a month-long calendar of events in November for Marrow Awareness Month. The events will culminate in a tribute at the World Trade Center, New York, to celebrate both the 10,000th transplant milestone and the legacy of the late Admiral E.R. Zumwalt Jr., USN (Ret), a founding father of the NMDP and The Marrow Foundation.

For information on how to become a donor, call 1-800-MARROW-2 or visit online at www.marrow.org.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.